Skip to main content
The Uromigos

The Uromigos

By The Uromigos

Broadcasting the latest developments in GU cancer
Available on
Apple Podcasts Logo
Google Podcasts Logo
Pocket Casts Logo
RadioPublic Logo
Spotify Logo
Currently playing episode

Episode 115: Triplet therapy for 1st line metastatic prostate cancer

The UromigosJul 01, 2021

00:00
23:20
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.
Mar 28, 202429:57
Episode 305: FDA and Oncology Clinical Trials

Episode 305: FDA and Oncology Clinical Trials

FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
Mar 19, 202429:35
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.
Mar 11, 202430:43
Episode 303: Community GU Oncology

Episode 303: Community GU Oncology

Michael Lattanzi discusses treatment plans and research in the community.
Mar 05, 202424:16
Episode 302: Part 2- Adjuvant Therapy in solid tumors

Episode 302: Part 2- Adjuvant Therapy in solid tumors

Hans Hammers discusses trial design and patient selection in the adjuvant setting.


Feb 25, 202434:37
Episode 301: Cancer research from a global perspective.

Episode 301: Cancer research from a global perspective.

Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries
Feb 20, 202431:07
Episode 300: Adjuvant PD1 Therapy in Solid Tumours

Episode 300: Adjuvant PD1 Therapy in Solid Tumours

David McDermott discusses melanoma and renal data. We never get to bladder or lung.
Feb 11, 202442:16
Episode 299: Androgen receptor ligand-directed degrader BMS-986365

Episode 299: Androgen receptor ligand-directed degrader BMS-986365

Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer
Feb 07, 202436:40
Episode 298: ASCO GU 2024 Highlights

Episode 298: ASCO GU 2024 Highlights

Silke, Tom and Brian cover the bases.

Jan 31, 202427:15
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath

Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath

Neeraj Agarwal addresses the issues raised at the meeting.
Jan 30, 202422:47
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan

Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005
Jan 27, 202423:58
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer

Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer

Pedro Barata summarises his ASCO GU discussion on this topic.
Jan 27, 202432:47
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer

Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer

Andrea Apolo describes the results of this positive trial.
Jan 27, 202433:18
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2

Episode 293: ASCO GU 2024: BRCAaway and CONTACT2

Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.
Jan 26, 202422:22
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer

Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer

Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
Jan 26, 202426:05
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer

Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer

Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
Jan 25, 202431:15
Episode 290: ASCO GU 2024 Preview

Episode 290: ASCO GU 2024 Preview

What to look out for in bladder, prostate and renal cancer at this year's meeting.
Jan 17, 202426:59
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine

Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine

Karim Fizazi discusses the clinical and biomarker components of this data.
Jan 15, 202436:02
Episode 288: APCCC #3: Controversies around Radiotherapy

Episode 288: APCCC #3: Controversies around Radiotherapy

Thomas Zilli discusses controversies around radiotherapy in prostate cancer.
Jan 10, 202436:29
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC

Episode 287 APCCC: Early Discontinuation of Therapy in HSPC

Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.
Jan 04, 202434:48
Episode 286: APCCC Prostate Cancer Meeting Overview

Episode 286: APCCC Prostate Cancer Meeting Overview

Silke Gillessen discusses this biannual meeting taking place in Lugano in March 2024.
Jan 03, 202430:23
Episode 285: Holiday Special: Renal Cancer in 2023

Episode 285: Holiday Special: Renal Cancer in 2023

Cristina Suarez discusses the year in review.
Dec 22, 202326:02
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023

Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023

Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023


Dec 21, 202337:56
Episode 283: Holiday Special: Prostate Cancer in 2023

Episode 283: Holiday Special: Prostate Cancer in 2023

Tanya Dorff discusses her favourite prostate cancer studies of the year.

Dec 20, 202334:34
Episode 282: Holiday Special: Bladder Cancer in 2023

Episode 282: Holiday Special: Bladder Cancer in 2023

Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.
Dec 13, 202338:12
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer

Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer

Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.

Dec 08, 202325:23
Episode 280: IKCS 2023 Overview

Episode 280: IKCS 2023 Overview

Tian Zhang discusses this fabulous renal cancer meeting. Belzutifan is covered too.
Nov 16, 202335:24
An apology

An apology

Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really sorry and will do everything we can to make sure it never happens again.
Nov 13, 202301:48
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023

Episode 279: Management of IO-resistant RCC at #UromigosLive 2023

Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
Nov 06, 202301:00:38
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023

Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023

Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary and secondary end points of VISION, current practice patterns, the right way to dose 177Lu-PSMA, PSMAfore, and more. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
Nov 04, 202339:32
Episode 277: NMIBC Discussion at #UromigosLive 2023

Episode 277: NMIBC Discussion at #UromigosLive 2023

Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Nov 04, 202344:05
Episode 276: ESMO 2023 Highlights

Episode 276: ESMO 2023 Highlights

Silke Gillessen joins Tom and Brian to give a summary of the meeting,
Oct 28, 202349:08
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville

Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville

Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.


Oct 27, 202313:31
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise

Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise

Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.
Oct 27, 202319:47
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC

Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC

Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng
Oct 26, 202313:47
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer

Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer

Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)
Oct 22, 202331:32
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer

Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer

Yohann Loriot described the 2 Thor randomised phase 3 studies


Oct 22, 202323:31
Episode 270: ESMO 2023 - Belzutifan in renal cancer

Episode 270: ESMO 2023 - Belzutifan in renal cancer

Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer
Oct 21, 202328:26
Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC

Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC

Brad McGregor discuses the DAD trial exploring this combo for the 1st time
Oct 21, 202324:53
Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett

Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett

Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Oct 20, 202327:07
Episode 267: ESMO preview - things to look out for at the meeting

Episode 267: ESMO preview - things to look out for at the meeting

Silke Gillessen, Brian and Tom look at ESMO 2023 GU track and beyond
Oct 11, 202327:06
Episode 266: Radiotherapy for prostate cancer

Episode 266: Radiotherapy for prostate cancer

Nick James discusses the optimal patients for radiotherapy and his approach to perioperative hormone therapy
Oct 10, 202328:46
Episode 265: Brachytherapy with Jeff Michalski

Episode 265: Brachytherapy with Jeff Michalski

Paper of the month: a randomised trial of brachytherapy vs external beam.


Oct 03, 202340:03
Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial

Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial

Jim Catto describes the 17 yr follow up data from this large prostate cancer study.
Sep 27, 202329:52
Episode 263: Toni Choueiri and papillary renal cancer

Episode 263: Toni Choueiri and papillary renal cancer

We describes progress in system therapy for advanced papillary RCC. Opportunities and challenges around personalised therapy are discussed
Sep 20, 202336:21
Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.

Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.

Susan Slovin describes her JCO investigator initiated R2 study which show the addition of cabazitaxel to abiraterone may be of benefit in CRPC
Sep 12, 202330:35
Episode 261: part 2 ctDNA in bladder cancer

Episode 261: part 2 ctDNA in bladder cancer

Matt Galsky completes the discussion on the rapidly moving topic.
Sep 04, 202340:29
Episode 260: Celeste Simon: how to make a career in translation science work.

Episode 260: Celeste Simon: how to make a career in translation science work.

Celeste shares her thoughts on her career in the lab, collaboration and working with clinicians. She also talks about things that went well and things that went less wells
Aug 30, 202326:25
Episode 259: Cystectomy for bladder cancer

Episode 259: Cystectomy for bladder cancer

Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya


Aug 24, 202325:29
Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1

Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1

Ananya Choudhury discussed the evidence for RT/TMT instead of surgery in muscle invasive bladder cancer. Regina Barragan-Carrillo (Golden Ticket Winner) introduces the podcast.
Aug 15, 202346:19